Today, a brief rundown of news involving Ionis Pharmaceuticals and the Food and Drug Administration, as well as updates from Zealand Pharma, Sangamo Biosciences and Novartis that you may have missed.
A new type of obesity drug being developed by Novo Nordisk has fallen short of expectations set by the company in a closely watched Phase 3 trial, causing shares to lose nearly a fifth of their value ...
Dec. 21, 2024 – Dec. 31, 2024 • New York, NY, USA, New York ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback